Background Therapeutic vaccines for cancer are an attractive alternative to conventional therapies, since the later result in serious adverse eVects and in most cases are not eVective against advanced disease. Human papillomavirus (HPV) is responsible for several malignancies such as cervical carcinoma. Vaccines targeting oncogenic viral proteins like HPV16-E6 and HPV16-E7 are ideal candidates to elicit strong immune responses without generating autoimmunity because: (1) these products are not expressed in normal cells and (2) their expression is required to maintain the malignant phenotype. Our group has developed peptide vaccination strategy called TriVax, which is eVective in generating vast numbers of antigen-speciWc T cells in mice capable of persisting for long time periods. Materials and methods We have used two HPV-induced mouse cancer models (TC-1 and C3.43) to evaluate the immunogenicity and therapeutic eYcacy of TriVax prepared with the immunodominant CD8 T-cell epitope HPV16-E7 49-57 , mixed with poly-IC adjuvant and costimulatory anti-CD40 antibodies. Results TriVax using HPV16-E7 49-57 induced large and persistent T-cell responses that were therapeutically eVective against established HPV16-E7 expressing tumors. In most cases, TriVax was successful in attaining complete rejections of 6-11-day established tumors. In addition, TriVax induced long-term immunological memory, which prevented tumor recurrences. The anti-tumor eVects of TriVax were independent of NK and CD4 T cells and, surprisingly, did not rely to a great extent on type-I or type-II interferon. Conclusions These Wndings indicate that the TriVax strategy is an appealing immunotherapeutic approach for the treatment of established viral-induced tumors. We believe that these studies may help to launch more eVective and less invasive therapeutic vaccines for HPV-mediated malignancies.
Introduction
Cervical cancer is the second most prevalent cancer among women. Human papillomavirus (HPV) causes 99 % of cervical cancer (CC), and the HPV16 and HPV18 genotypes account for 70 % these cases [1] . Worldwide, CC is responsible for »250 000 deaths per year and for causing a huge economic burden in related health care costs [2, 3] . The current approved prophylactic vaccines for HPV are not useful for treating established malignant disease, nor can protect already infected individuals from developing cancer [4] [5] [6] . Most importantly, a signiWcant proportion of women, especially in the third world, will not receive the prophylactic vaccines and will continue to be at high risk of developing CC [7] . Because, conventional therapies for CC are usually devastating, invasive, toxic, and associated with 10 % recurrence [8] , there is an urgent need for developing alternative treatments such as immunotherapy and, more speciWcally, therapeutic vaccines.
CD8 T lymphocytes are the most eVective components of the adaptive immune system capable of recognizing and destroying viral-infected and transformed malignant cells [9] [10] [11] . The antigens recognized by CD8 T cells on their target cells are small peptides derived from viral or tumor-associated antigens (TAAs) that associate with cell surface class I products of the major histocompatibility complex (MHC-I). In the case of cells transformed by HPV, peptide sequences derived from the oncogenic E6 and E7 viral proteins have been shown to represent suitable TAAs for CC and are considered as ideal candidates for developing therapeutic vaccines [12] [13] [14] [15] [16] [17] [18] . Synthetic peptides representing these TAAs have been tested in numerous ways in patients and mouse cancer models for their ability to generate anti-tumor T-cell responses capable of exhibiting anti-tumor eVects [12, 16, 17, [19] [20] [21] . However, in most instances, only modest T-cell responses capable of dealing with very early disease stages were obtained, indicating that improved peptide-based immunization strategies need to be developed to have a signiWcant impact against established and advanced disease stages. Our laboratory has recently described an improved peptide vaccination strategy capable of generating in mice vast numbers of CD8 T cells capable of persisting for long time periods [22, 23] . This vaccine called TriVax consists of a synthetic peptide corresponding to the minimal T-cell epitope, poly-IC adjuvant, and costimulatory monoclonal anti-CD40 antibodies ( CD40 mAb), which are mixed together and administered intravenously. After two sequential TriVax immunizations (prime/boost) with the well-known Ova 257-264 T-cell epitope, up to 80 % of all the CD8 T cells in blood were antigen speciWc, and more than half of these cells persisted for at least 60 days [23] . The goal of the present study was to evaluate the eYcacy of TriVax in an HPV cancer mouse model. The results demonstrate that TriVax using peptide HPV16-E7 49-57 induced large and persistent T-cell responses that were eVective against two diVerent tumors expressing HPV16-E7. Interestingly, the anti-tumor eVects of TriVax in this tumor model appeared to be independent of NK and CD4 T cells and did not rely to a great extent on either type-I or -II interferons. We believe that the results from these studies may help to develop more eVective therapeutic vaccines for CC.
Materials and methods

Mice
Six-to nine-week-old female C57BL/6 (B6) mice were obtained from the National Cancer Institute/Charles River program (Wilmington, MA). Interferon-gamma (IFN ) knockout (KO) mice in the B6 background were purchased from Jackson Laboratories (Bar Harbor, ME). IFN receptor KO (IFN R KO) mice also in the B6 background were obtained from Dr. Philippa Marrack (National Jewish Medical and Research Center, Denver, CO). All animal care and experiments were conducted according to our institutional animal care and use committee guidelines.
Cell lines
TC-1 tumor cells, obtained from Dr. T-C Wu (Johns Hopkins University, Baltimore, MD), were derived from primary lung epithelial cells of B6 mice and express HPV16-E6 and E7 proteins [24] . The C3.43 tumor cell line obtained from Dr. W. M. Kast (University of Southern California, Los Angeles, CA) is an aggressive derivative of the C3 line (B6 background), which was transformed using a pRSVneo-derived plasmid containing the complete HPV16 genome [19] . The EL4 cell line was purchased from the American Type Culture Collection (Manassas, VA). All cells were maintained in tissue culture following the recommendations of the providers.
Peptides, MHC-I tetramer, and antibodies
The synthetic peptide RAHYNIVTF from HPV16-E7 (E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] ), deWned as an immunodominant H-2Db-restricted CD8 Tcell epitope [19, 25] , and control peptide NAYVFKGL from chicken ovalbumin (Ova 176-183 ) were purchased as >95 % pure from A&A Labs (San Diego, CA). Rat anti-mouse CD40 (FGK45.5) anti-NK1.1 (PK136), anti-CD4 (GK1.5), and anti-CD8 (2.43) monoclonal antibodies were prepared from hybridoma culture supernatants. The E7 49-57 /H-2Db tetramers labeled with Alexa 647 were provided by the National Institute of Allergy and Infectious Disease Tetramer Facility at the Emory University (Atlanta, GA from NIH). Fluorochrome-labeled antibodies speciWc for mouse CD8a (53-6.7) and MHC-II (M5/114.15.2) were from eBioscience, Inc (San Diego, CA).
Immunizations
Mice were usually vaccinated via the i.v. route (unless otherwise noted). TriVax consisted of a mixture of 30 g of the E7 49-57 peptide, 100 g CD40 mAb, and 50 g of poly-IC (Poly-ICLC, Oncovir, Inc.). BiVax contained only the peptide and poly-IC at the same amounts. In all cases, mice are given two sequential vaccinations 13 days apart (prime and boost). In some cases, mice received peptide alone or peptide with CD40 mAb.
Immunological assays
For tetramer staining, either peripheral blood samples (»3-5 drops) taken from the submandibular vein or splenocytes were stained with a mixture of antibodies to MHC-II, CD8a (eBioscience; San Diego, CA), and tetramer for 40 min in ice. After washing with three times, the Xuorescence was evaluated using an LSRII Xow cytometer (BD Biosciences) and analyzed using FlowJo software (Ashland, OR). Results are presented as percentage tetramer-positive cells of the CD8+/MHC-II negative population. To determine whether CD8 T cells were able to recognize tumor cell lines (TC-1, C3.43) expressing the naturally processed peptide, IFN , enzyme-linked immunosorbent spot (EliSpot) assays were performed as described [26] . BrieXy, CD8 T cells from spleens of vaccinated mice were puriWed by positive selection using antibody-coated magnetic beads (Miltenyi Biotec, Auburn, CA). Responder (CD8-puriWed) cells were incubated at 3 £ 10 5 , 1 £ 10
5
, and 3 £ 10 4 per well, together with 1 £ 10 5 stimulator cells (EL4, plus/minus peptide, TC-1, and C3.43 cells pretreated or not for 24 h with 100 ng/ml IFN ). Cultures were incubated at 37°C for 20 h, and spots (IFN -producing cells) were developed as described by the EliSpot kit manufacturer (Mabtech, Inc., Mariemont, OH). Spot counting was done with an AID EliSpot Reader System (Autoimmun Diagnostika GmbH, Strassberg, Germany).
Evaluation of therapeutic anti-tumor eVects
Mice received 3 £ 10 5 /mouse tumor cells (TC-1 or C3.43) s.c. in a shaved rear Xank 6 or 11 days (as noted) before their Wrst immunization. In some instances, survivor mice were re-challenged with the same number of tumor cells (in opposite Xanks). To determine the contribution of diVerent subsets of lymphocytes, the anti-tumor eVect of the vaccine, NK, CD4, and CD8 cell antibody-depleted mice and KO mice was compared with B6 wild-type (WT) mice. For cell depletions, each mouse received 300 g anti-NK1.1, 300 g anti-CD4, or 500 g anti-CD8 twice on days ¡2 and 0 before immunization. Depletions were conWrmed by analysis of blood samples using Xow cytometry (data not presented). Tumor growth was monitored every 2-4 days in individual tagged mice by measuring 2 opposing diameters with a set of calipers. Mice were killed when the tumor area reached 400 mm 2 . Results are presented as the mean tumor size (area in mm 2 ) § SD for every treatment group at various time points until the termination of the experiment.
Statistical analyses
Statistical signiWcance of the numbers of antigen speciWc CD8 T cells (EliSpot), cytokine levels (ELISA) and absolute number of lung tumor nodules was assessed using unpaired Student's t tests. Tumor sizes between 2 populations throughout time were analyzed for signiWcance using 2-way ANOVA tests. All analysis and graphics were done using GraphPad Prism 5.01 (GraphPad Software, San Diego, CA).
Results
Evaluation of TriVax immunization using a peptide epitope from HPV16-E7
Residues 49-57 of the HPV16-E7 protein (RAHYNIVTF) correspond an immunodominant CD8 T-cell epitope restricted by the H-2Db MHC-I molecule [19, 25] . We Wrst determined the ability of synthetic peptide E7 49-57 representing this sequence to elicit an immune response when administered to mice in combination with poly-IC and CD40 mAb, a vaccine formulation known as TriVax. In addition, we compared the immunogenicity of vaccines containing peptide alone, peptide plus poly-IC (BiVax), or peptide plus CD40 mAb. Antigen-speciWc immune responses were measured using tetramer analysis six days after the prime and booster immunizations and at various time points thereafter. As shown in Fig. 1a , TriVax and BiVax induced very high number of antigen-speciWc (tetramer positive) CD8 T cells after the booster immunization, which persisted at high levels for several weeks (Fig. 1b) . On the other hand, administration of the E7 49-57 peptide alone or in combination with CD40 mAb failed to generate a signiWcant immune response. More importantly, spleen CD8 T cells from TriVax-and BiVax-immunized mice were shown to be very eVective in recognizing E7 49-57 peptide-pulsed target cells (EL4) and TC-1 tumor cells, which express the HPV16-E7 protein and naturally process the antigen (Fig. 1c) .
Anti-tumor eVectiveness of TriVax
The therapeutic anti-tumor eVects of the 4 modes of peptide vaccination were assessed. Mice bearing 6-day established TC-1 tumors received the peptide vaccines (prime/boost), and tumor sizes and immune responses were measured at various time points. As shown on Fig. 2a , tumor growth was eVectively controlled in those mice that received TriVax, BiVax, and, to some extent, peptide E7 49-57 with CD40 mAb, as compared to mice vaccinated with E7 49-57 alone (where tumors grew at an accelerated rate and mice had to be euthanatized by day 22). Notably, 100 % of the mice that received TriVax and 33 % of those receiving BiVax completely rejected their tumors, while in the case of the mice immunized with E7 49-57 with CD40 mAb, although the tumors grew at a slow rate, none were rejected. Measurements of the immune responses elicited by these vaccines in the tumor-bearing mice (Fig. 2b indicated that both TriVax and BiVax induced high numbers of persisting E7 49-57 -speciWc CD8 T cells. Interestingly, the diVerences between TriVax and BiVax were less apparent as compared to those observed in tumor-free mice (Fig. 1b) . E7 49-57 with CD40 mAb induced a small CD8 Tcell response (between 3 and 5 % tetramer-positive cells), but apparently strong enough to reduce the tumor growth. No appreciable immune response was observed in mice that received E7 49-57 alone. The therapeutic eVect of TriVax with E7 49-57 was antigen speciWc since TriVax prepared with an irrelevant peptide (Ova 176-183 ) was not eVective in reducing the rate of tumor growth (Fig. 2c) . The therapeutic eVects observed with E7 49-57 BiVax (Fig. 2a) were conWrmed in an additional experiment using a larger number of mice (6) , where in this case, this therapeutic vaccination strategy resulted in 50 % complete tumor rejections (Fig. 2d) . Moreover, when BiVax was administered three times (prime plus 2 boosts, 7 days apart), rejections were observed in 100 % of the mice (data not presented).
The impressive therapeutic anti-tumor eVects observed with E7 49-57 TriVax was evaluated against larger and more established TC-1 tumors. The results shown in Fig. 3a demonstrate that therapeutic immunization with TriVax 11 days post-tumor inoculation resulted in 100 % complete rejections and increased survival. The therapeutic eVectiveness of E7 49-57 TriVax was also examined using a diVerent tumor cell line called C3.43, which also expresses the HPV16-E7 antigen. As presented in Fig. 3b , TriVax using the E7 49-57 peptide resulted in complete rejection of 6-day established C3.43 tumors. Furthermore, at the conclusion of this experiment (day 30), considerable numbers of E7 49-57 -speciWc CD8 T cells remained [49] [50] [51] [52] [53] [54] [55] [56] [57] BiVax were conWrmed using a larger number of mice (6/group). In this experiment, half (3/6) of the mice in the BiVax-vaccinated group rejected their tumor, while all mice in the control group did not present on the spleens of the TriVax-immunized mice (Fig. 3c) . Moreover, the spleen CD8 T cells from the TriVax-immunized mice that rejected the C3.43 tumors were eVective in recognizing C3.43 and TC-1 tumors, and such recognition was increased to some extent by interferon-gamma (IFN ) pretreatment of the tumor cells (Fig. 3d) , which enhances the expression levels of MHC-I on both tumors (data not shown). TriVax generates immunological memory that prevents tumor recurrences
An eVective therapeutic vaccination strategy should generate immune responses capable not only of eliminating tumor masses but also should be successful in preventing tumor recurrences by generating long-term immune memory. Thus, we evaluated whether E7 49-57 TriVax-treated mice that had successfully rejected TC-1 tumors would be able to respond to subsequent tumor re-challenges. The experiment shown in Fig. 3e shows that »1 month after rejecting their original TC-1 tumors, TriVax-immunized mice successfully resisted second tumor challenges using TC-1 and C3.43 cells, which were given separately to each mouse in opposite posterior Xanks. Unvaccinated control mice developed both tumor challenges, which grew at an accelerated rate.
EVect of route of administration in TriVax
The results presented so far were obtained using immunizations that were administered intravenously (i.v.) since the goal was to generate a systemic immune response. However, since vaccines are generally not administered via the i.v. route, we examined whether TriVax would be eVective against 6-day established TC-1 tumors if it were administered intramuscularly (i.m.). As shown in Fig. 4a, i .m. E7 49-57 TriVax induced tumor clearance of 100 % of treated mice, while tumors in the non-vaccinated mice grew at a fast rate. Notably, the frequency of antigen-speciWc (tetramer positive) CD8 T cells in blood of these mice, measured 11 days after the booster immunization, was rather low (range 2.3-10.5 %, Fig. 4b ), compared to the values we routinely observed in mice immunized i.v. (>50 %). In addition, one of the six i.m. vaccinated mice in this experiment (the one with the lowest numbers of antigen-speciWc CD8 T cells) developed a tumor recurrence at the original injection site on day 82 (post prime), suggesting that the tumor had not been totally eradicated.
Mechanism of anti-tumor eVects of TriVax
Lastly, to assess the roles of various lymphocyte subsets and the requirements of eVector cytokines, the anti-tumor eYcacy of E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] TriVax was examined in CD8-, CD4-, and NK-depleted mice and in IFN KO and IFN R KO mice. The results in Fig. 5a show, as expected, that mice depleted of CD8 T cells were unable to control tumor growth and closely resembled the non-vaccinated mice. On the other hand, 100 % of the CD4-and NK cell-depleted mice rejected their tumors. Surprisingly, the TriVax-immunized IFN KO and IFN R KO mice were able to control tumor growth to a great degree, and in some instances, complete rejections were observed (Fig. 5b) . When the intensity of the CD8 T-cell responses in immunized IFN and IFN R KO tumor-free mice was evaluated after TriVax immunization (prime/boost), it became evident that absence of IFN had little eVect, while the role of type-I IFN in generating high CD8 T-cell numbers was clearly more important (Fig. 5c ).
Discussion
The goal of the present studies was to assess the eVectiveness of a new and potent peptide vaccination strategy for its therapeutic eVectiveness against tumors expressing the HPV16-E7 oncogene product. This viral product is an ideal TAA for developing T cell-based immunotherapy against (TriVax IM) and an identical booster was given on day 13. Tumor growth was measured as described previously. By day 25, all mice (6/6) vaccinated with TriVax rejected tumor, but by day 66, one of the mice developed a tumor mass at the original site (not shown). All of the (3/3) non-vaccinated mice developed large tumors and did not survive. b Frequency of antigen-speciWc CD8 T cells (tetramer positive) in the blood of the mice shown in a measured 11 days after boost. Numbers below the oval gates represent the % tetramer-positive cells of the CD8 T-cell population HPV-transformed cells because it is recognized as a foreign antigen. Thus, the lack of immunological tolerance allows the generation of high-avidity T-cell responses, which contrasts with lower-avidity T cells generated against other types of TAAs that are expressed by normal tissues (e.g., melanosomal products, p53, HER2/neu). We have reported that TriVax using epitopes from melanosomal TAA such as Trp1 and Trp2 that are expressed on normal cells, although generate large numbers of antigen-speciWc T cells that diminish tumor growth, are incapable of rejecting established B16 melanomas in WT mice [23, 27] .
Because the HPV16-E7 protein plays a critical role in maintaining the transformed phenotype of the tumor cells [28, 29] , the possible appearance of antigen-loss mutants, which is often seen in immunotherapy [10] , should be diminished. The results presented here using two HPV16 mouse tumor models (TC-1 and C3.43) demonstrate that immunization with a synthetic peptide representing an exact CD8 T-cell epitope in combination with poly-IC and CD40 mAb (TriVax) resulted in extensive antigen-speciWc T-cell responses that were durable and capable of eradicating established tumors. Others have reported that vaccines prepared with the minimal CD8 T-cell epitopes, especially when administered systemically, are ineVective because the peptides can be presented by non-professional antigen-presenting cells (APCs) resulting in T-cell tolerance [30] [31] [32] . For this reason, some investigators advocate the use of long synthetic peptides that require antigen processing by professional APCs [20] . The present results and previous work by our group [22, 23] demonstrate that vaccines containing minimal CD8 T-cell epitopes can be highly immunogenic when provided together with poly-IC and CD40 mAb and in some cases with poly-IC alone (Fig. 1) . In fact, to the best of our knowledge, the magnitude of the responses we have observed with several minimal CD8 T-cell epitopes using TriVax (HPV16-E7 49-57 , Trp1 455-463/9M , Trp2 180-188 , Ova 257-264 , rNEU [66] [67] [68] [69] [70] [71] [72] [73] [74] ) is far superior to what has been reported using other peptide vaccines (with either short or long synthetic peptides), when administered with conventional adjuvants (e.g., IFA), pulsed onto DCs or when using recombinant DNA vaccines. Although the magnitude of the T-cell responses achieved with TriVax in mice is impressive, we do not know whether similar eVects can be accomplished in humans following the same strategy. Moreover, it will be important to assess and closely monitor those potential Although the combination of all three components of TriVax was clearly the most eVective therapeutic strategy, possibly because it generated the strongest immune responses (Fig. 1a, b) , immunization with peptide and poly-IC (BiVax) or peptide plus CD40 mAb was also quite eVective in eliciting CD8 T-cell responses that resulted in signiWcant therapeutic beneWt (Figs. 1, 2) . These results indicate that the CD40 mAb potentiates the eVectiveness of TriVax, but is not essential and that poly-IC plays the major role of adjuvant in this vaccination strategy. It is possible that with additional immunization boosters, the eYcacy of BiVax could improve to the level of TriVax to attain 100 % tumor rejections by increasing T-cell numbers. On the other hand, we cannot rule out that the CD40 mAb may facilitate the generation of CD8 T cells with increased function and that simply inducing high numbers of T cells will be insuYcient to achieve maximal therapeutic responses. Notwithstanding, our results indicate that even low numbers of antigen-speciWc CD8 T cells, which were induced by peptide plus CD40 mAb, and TriVax administered i.m. were suYcient to eVectively control the rate of tumor growth. However, complete and durable rejections in all mice were only achieved when high numbers of antigen-speciWc CD8 T cells were produced.
The rationale for the use of CD40 mAb in the generation of CD8 T-cell responses is to provide the strong costimulatory signal to antigen-presenting dendritic cells (DCs), which is usually supplied by CD40 ligand (CD40L) expressing CD4 T helper cells. The CD40/CD40L costimulatory interaction has been proposed to be critical for the generation of memory CD8 T cells capable of persisting for long time periods [33] . Nevertheless, BiVax showed to be eVective in generating high numbers of long-lasting CD8 T-cell responses, presumably in the absence of CD40 ligation. Furthermore, depletion of CD4 T cells does not decrease (but slightly increases) the generation of antigenspeciWc CD8 T cells by BiVax (data not presented), ruling out that this vaccine somehow also stimulates CD4 T cells. The ability of BiVax to trigger strong T-cell responses to the E7 49-57 peptide appears to be somewhat unique, since other potent CD8 T-cell epitopes such as Ova 257-264 (SIINFEKL) and melanoma Trp1 455-463/9M (TAPDNLGYM) are ineVective and require CD40 mAb in addition to poly-IC (E. Celis, unpublished). SpeciWc characteristics such as solubility that could inXuence the formation of micro-aggregates and serum protease resistance aVecting the peptide's pharmacokinetics are likely to determine in great part whether a peptide is able to trigger T-cell responses when administered in the BiVax format. Poly-IC is a double-stranded synthetic RNA that stimulates TLR3 and cytoplasmic RNA helicases (RIG-I and MDA5) resulting in the activation of DCs and the generation of high amounts of type-I IFN [34, 35] , which is considered important for the induction of eVective T-cell responses [36] . Our results indicate that in the absence of type-I IFN signaling (in IFN R KO mice), TriVax was less eVective in generating suYcient numbers of CD8 T cells that could be necessary for total disease eradication (Fig. 5b, c) . Nevertheless, it was interesting to note a substantial anti-tumor eVect of TriVax in the absence of type-I IFN signals, which could be due to the participation of other T-cell stimulatory cytokines such as IL-12 generated by the combination of poly-IC and CD40 mAb. It was somewhat unexpected to observe a signiWcant anti-tumor eVect of TriVax in the absence of IFN (Fig. 5b) , since this cytokine is considered to be critical for the anti-tumor eVects of CD8 T cells [37] [38] [39] . Nevertheless, our results indicate that IFN may play some role in the overall eVectiveness of TriVax to completely reject the tumors. These results contrast with our recent Wndings in the B16 melanoma system in which IFN was shown to play a negative role in the anti-tumor eVects of TriVax using Trp1 455-463/9M and Trp2 280-288 , where complete rejections of established tumors were observed in IFN KO mice and not in WT mice [27] . Thus, it is possible that IFN plays an eVector role with the TC-1 tumors, limiting cell proliferation or that the increase MHC-I expression induced by IFN in these cells enhances T-cell recognition.
In summary, the results presented herein in a mouse model of HPV-induced cancer demonstrate the feasibility of a novel and potent peptide vaccination strategy that could be adopted for CC or other HPV-induced malignancies. Both poly-IC and CD40 mAb for human clinical use are in development and together with known human CD8 T-cell epitopes could be administered using the TriVax format with the goal of reducing tumor growth and, perhaps as shown here in mice, eradicate established disease.
